AU2022207514A1 — Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions
Assigned to Antecip Bioventures II LLC · Expires 2023-07-27 · 3y expired
What this patent protects
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
USPTO Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.